WO2003082908A3 - Use of the p17 protein of hiv in isolated form for the preparation of a medicament for administration to hiv seropositive patients, as well as pharmaceutical compositions comprising said protein - Google Patents

Use of the p17 protein of hiv in isolated form for the preparation of a medicament for administration to hiv seropositive patients, as well as pharmaceutical compositions comprising said protein Download PDF

Info

Publication number
WO2003082908A3
WO2003082908A3 PCT/EP2003/003177 EP0303177W WO03082908A3 WO 2003082908 A3 WO2003082908 A3 WO 2003082908A3 EP 0303177 W EP0303177 W EP 0303177W WO 03082908 A3 WO03082908 A3 WO 03082908A3
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
protein
medicament
administration
preparation
Prior art date
Application number
PCT/EP2003/003177
Other languages
French (fr)
Other versions
WO2003082908A2 (en
Inventor
Arnaldo Caruso
Original Assignee
Medestea Internaz S R L
Arnaldo Caruso
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medestea Internaz S R L, Arnaldo Caruso filed Critical Medestea Internaz S R L
Priority to AU2003219101A priority Critical patent/AU2003219101A1/en
Publication of WO2003082908A2 publication Critical patent/WO2003082908A2/en
Publication of WO2003082908A3 publication Critical patent/WO2003082908A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

The invention relates to a medicament for booster antigen use in HIV seropositive patients which uses, as active ingredient, the p17 protein of HIV or variants thereof in isolated or DNA form, containing sequences encoding for p17 or its variants which, if administered alone or combined with anti-inflammatory cytokines and molecules or DNA encoding for anti-inflammatory cytokines, are able to evoke or increase the serum titre of the anti-HIV-p17 antibodies that are capable of neutralizing the immunostimulating activity of the viral protein.
PCT/EP2003/003177 2002-03-29 2003-03-27 Use of the p17 protein of hiv in isolated form for the preparation of a medicament for administration to hiv seropositive patients, as well as pharmaceutical compositions comprising said protein WO2003082908A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003219101A AU2003219101A1 (en) 2002-03-29 2003-03-27 Use of the p17 protein of hiv in isolated form for the preparation of a medicament for administration to hiv seropositive patients, as well as pharmaceutical compositions comprising said protein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2002TO000286A ITTO20020286A1 (en) 2002-03-29 2002-03-29 USE OF THE PROTEIN P17 ISOLATED FOR THE PREPARATION OF A MEDICATION SUITABLE TO INHIBIT THE IMMUNOSTIMULATING EFFECTS THAT THE PROTEIN PRODUCED D
ITTO2002A000286 2002-03-29

Publications (2)

Publication Number Publication Date
WO2003082908A2 WO2003082908A2 (en) 2003-10-09
WO2003082908A3 true WO2003082908A3 (en) 2004-03-25

Family

ID=27638968

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/003177 WO2003082908A2 (en) 2002-03-29 2003-03-27 Use of the p17 protein of hiv in isolated form for the preparation of a medicament for administration to hiv seropositive patients, as well as pharmaceutical compositions comprising said protein

Country Status (3)

Country Link
AU (1) AU2003219101A1 (en)
IT (1) ITTO20020286A1 (en)
WO (1) WO2003082908A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITTO20080027A1 (en) 2008-01-15 2009-07-16 Medestea Res & Production S P A SHAPED FORM OF HIV PROTEIN P17.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0293792A2 (en) * 1987-06-01 1988-12-07 The Du Pont Merck Pharmaceutical Company Human immunodeficiency virus GAG-encoded proteins
EP0322394A2 (en) * 1987-11-24 1989-06-28 Smithkline Biologicals S.A. Expression of HIV proteins in E. coli and S. cerevisiae
WO1998037089A2 (en) * 1997-02-24 1998-08-27 Oxford Biomedica (Uk) Limited Matrix derived anti-hiv peptides and transdominant proteins
WO2003016337A1 (en) * 2001-08-07 2003-02-27 Medestea Internazionale S.R.L. Isolated polypeptides based on the neutralizing epitope of the p17 protein of hiv useful as vaccines, and neutralizing anti-p17 antibodies which specifically recognize said neutralizing epitope

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0293792A2 (en) * 1987-06-01 1988-12-07 The Du Pont Merck Pharmaceutical Company Human immunodeficiency virus GAG-encoded proteins
EP0322394A2 (en) * 1987-11-24 1989-06-28 Smithkline Biologicals S.A. Expression of HIV proteins in E. coli and S. cerevisiae
WO1998037089A2 (en) * 1997-02-24 1998-08-27 Oxford Biomedica (Uk) Limited Matrix derived anti-hiv peptides and transdominant proteins
WO2003016337A1 (en) * 2001-08-07 2003-02-27 Medestea Internazionale S.R.L. Isolated polypeptides based on the neutralizing epitope of the p17 protein of hiv useful as vaccines, and neutralizing anti-p17 antibodies which specifically recognize said neutralizing epitope

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CARUSO ARNALDO ET AL: "HIV-1 matrix protein p17 increases the production of proinflammatory cytokines and counteracts IL-4 activity by binding to a cellular receptor", FASEB JOURNAL, vol. 16, no. 4, 20 March 2002 (2002-03-20), Annual Meeting of the Professional Research Scientists on Experimental Biology;New Orleans, Louisiana, USA; April 20-24, 2002, pages A294, XP009019455, ISSN: 0892-6638 *
FERNANDES J C ET AL: "THE ROLE CYTOKINES IN OSTEOARTHRITIS PATHOPHYSIOLOGY", BIORHEOLOGY, ELSEVIER SCIENCE LTD., OXFORD, GB, vol. 39, no. 1/2, April 2001 (2001-04-01), pages 237 - 246, XP008009498, ISSN: 0006-355X *
FRANCESCO DE M A ET AL: "HIV-1 matrix protein p17 increases the production of proinflammatory cytokines and counteracts IL-4 activity by binding to a cellular receptor", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 99, no. 15, 23 July 2002 (2002-07-23), pages 9972 - 9977, XP002234153, ISSN: 0027-8424 *
KIM J J ET AL: "CYTOKINE MOLECULAR ADJUVANTS MODULATE IMMUNE RESPONSES INDUCED BY DNA VACCINE CONSTRUCTS FOR HIV-1 AND SIV", JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, MARY ANN LIEBERT, NEW YORK, NY, US, vol. 19, no. 1, January 1999 (1999-01-01), pages 77 - 84, XP000971666, ISSN: 1079-9907 *
ORLIKOWSKY THORSTEN W ET AL: "Dexamethasone inhibits CD4 T cell deletion mediated by macrophages from human immunodeficiency virus-infected persons", JOURNAL OF INFECTIOUS DISEASES, vol. 184, no. 10, 15 November 2001 (2001-11-15), pages 1328 - 1330, XP002258403, ISSN: 0022-1899 *

Also Published As

Publication number Publication date
AU2003219101A8 (en) 2003-10-13
ITTO20020286A1 (en) 2003-09-29
AU2003219101A1 (en) 2003-10-13
WO2003082908A2 (en) 2003-10-09
ITTO20020286A0 (en) 2002-03-29

Similar Documents

Publication Publication Date Title
WO2004071426A3 (en) Compounds for the treatment of viral infection
JPH0125A (en) Pharmaceutical composition for treating HIV infection comprising dsRNA and reverse transcriptase inhibitor
WO2006002079A8 (en) Hiv-1 neutralizing antibodies elicited by trimeric hiv-1 envelope glycoprotein complex
JP2003535043A5 (en)
HUP0402259A2 (en) Vaccines
WO2006017505A3 (en) Pharmaceutical formulations comprising pleconaril for the treatment of airway diseases
CY1105408T1 (en) USE OF PARAPOX OVIS VIRUS STRAINS FOR THE PREPARATION OF ANCIENT MEDICINES AND ANTI-CANCER DRUGS
WO2005085268A3 (en) Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production
HK1068606A1 (en) Novel aminobenzoephenones
WO2004054607A3 (en) Stable therapeutic proteins
WO2003087757A3 (en) Particle-bound human immunodeficiency virus envelope clycoproteins and related compositions and methods
WO2022010938A3 (en) Catalysis deactivated angiotensin-converting enzyme 2 (ace2) variants and their uses
EP2502998A3 (en) Recombinant toxin A/ToxinB vaccine against clostridium difficile
DE50105771D1 (en) IBUPROFEN-ACTIVE PREPARATION
WO2002078631A3 (en) Improved conditionally replicating vectors for inhibiting viral infections
HUP0400698A2 (en) Modified interleukin-1 receptor antagonist (il-1ra) with reduced immunogenicity
WO2003082908A3 (en) Use of the p17 protein of hiv in isolated form for the preparation of a medicament for administration to hiv seropositive patients, as well as pharmaceutical compositions comprising said protein
EP1133997A3 (en) Treatment of immune diseases with beta-interferon
JP2004538334A (en) Drugs used in the treatment of HIV infection and their components and uses
AU1976100A (en) Viral vaccine
WO2000066173A3 (en) Targeting of infectious agents bearing host cell proteins
WO2004006830A3 (en) Use of ccn protein family members for the treatment of disorder associated to an altered calcium and/or sodium flux
WO2006030323A3 (en) Compounds that inhibit replication of human immunodeficiency virus
WO2002053096A3 (en) Single therapy and combination therapy involving drugs with target cellular proteins and drugs which target pathogen-encoded proteins
EP1583545A4 (en) Pharmaceutical composition for improved administration of hiv gp41-derived peptides, and its use in therapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP